Intermittent androgen blockade should be regarded as standard therapy in prostate cancer

Nature Clinical Practice Oncology

Volumn 5, Issue 10, 2008, Pages 574-576

  Seruga, Bostjan ^a   Tannock, Ian F ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ANEMIA; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FLUID RETENTION; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; TREATMENT DURATION; WELLBEING;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 53749103325     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1180     Document Type: Article

References (10)

1. Thompson CA et al. (2003) Andropause: Symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8: 474-487
2. Braga-Basaria M et al. (2006) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24: 3979-3983
3. Keating NL et al. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456
4. Sato N et al. (1996) Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 58: 139-146
5. Akakura E et al. (1993) Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and prostate-specific antigen. Cancer 71: 2782-2790
6. de Leval J et al. (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 1: 163-171
7. Tunn UW (online 2007) Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507 [http://www.abstracts2view.com/aua_archive/view.php?nu=200791183] (accessed 17 June 2008)
8. Miller K et al. (2007) Randomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract]. J Clin Oncol 25 (Suppl 18S): 5015
9. Calais da Silva FM et al. (2006) Phase III study of intermittent MAB versus continuous MAB [abstract]. J Clin Oncol 24 (Suppl 18S): 4513
10. Prostate Cancer Trialist's Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials. Lancet 335: 1491-1498